Transplantation Direct (Jul 2020)

Donor-derived Cell-free DNA in Infections in Kidney Transplant Recipients: Case Series

  • Naeem Goussous, MD,
  • Wen Xie, MD,
  • Noor Dawany, PhD,
  • Joseph R. Scalea, MD,
  • Amanda Bartosic, MBA,
  • Abdolreza Haririan, MD,
  • Roberto Kalil, MD,
  • Cinthia Drachenberg, MD,
  • Nadiesda Costa, MD,
  • Matthew R. Weir, MD,
  • Jonathan S. Bromberg, MD, PhD

DOI
https://doi.org/10.1097/TXD.0000000000001019
Journal volume & issue
Vol. 6, no. 7
p. e568

Abstract

Read online

Background. Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive plasma biomarker to evaluate for transplant allograft rejection. The relationship between infectious complications in kidney allografts and dd-cfDNA has received cursory attention in prior publications. Methods. Retrospective review of all renal transplant recipients who underwent dd-cfDNA testing between November 2017 and August 2019. Results. We report on 7 cases in whom infections affecting the transplanted kidney were associated with elevation in dd-cfDNA without concomitant rejection or elevation in serum creatinine. Five patients had BK viremia, and 2 patients had urinary tract infection associated with elevated dd-cfDNA levels. Conclusions. These observations suggest that elevations in dd-cfDNA are not specific to kidney allograft rejection and can be associated with infections affecting the transplanted kidney. This biomarker may be valuable in evaluating infectious complications of kidney allografts.